...
机译:索拉非尼在不可切除的肝内胆管细胞癌中的一例报告
Department of Gastroenterology ampamp Hepatology AKH ampamp Medical University of Vienna Vienna Austria;
Department of Gastroenterology ampamp Hepatology AKH ampamp Medical University of Vienna Vienna Austria;
Department of Radiology AKH ampamp Medical University of Vienna Vienna Austria;
Department of Pathology AKH ampamp Medical University of Vienna Vienna Austria;
Department of Gastroenterology ampamp Hepatology AKH ampamp Medical University of Vienna Vienna Austria;
Cholangiocellular carcinoma; Sorafenib; Multikinase inhibitor; Angiogenesis;
机译:精密肝动脉伊立替康治疗不可切除的肝内胆管细胞癌的最佳耐受性和延长的总生存期。
机译:精确肝动脉伊立替康治疗不可切除的肝内胆管细胞癌的最佳耐受性和总体生存期的延长
机译:7147长期使用索拉非尼的疗效和安全性:索拉非尼在日本不可切除/转移性肾细胞癌患者中进行的II期临床试验的最终报告
机译:FK506肝内动脉和内部施用对肝移植肝癌肝移植存活的影响及可能预防大鼠肿瘤复发
机译:TWSG1,BMP4和Shh Morphogens信号蛋白在肝细胞癌和胆管细胞癌中的差异表达。
机译:索拉非尼治疗不可切除和晚期肝内胆管癌的有效性和安全性:一项初步研究
机译:先天性异常的肝内门静脉系统肝内胆管癌癌复杂化。案例报告。